High initial levels of comorbidity in patients with ra selected to receive biologic agents

Access through your institution Buy or subscribe Hyrich K _ et al_. (2006) Baseline comorbidity levels in biologic and standard DMARD treated patients with rheumatoid arthritis: results from

a national patient register. _Ann Rheum Dis_ 65: 895–898 Although the pivotal, randomized, controlled trials of biologic therapies for rheumatoid arthritis (RA) did not show an increase in

serious adverse events in biologic-agent-treated patients compared with placebo-treated patients, there has been concern about the safety of biologic agents in routine practice, because

those trials excluded patients with substantial comorbidity. Indeed, there have been reports of increases in serious adverse events in patients who receive biologic agents; however, before

these events can be attributed to the new treatments, the baseline comorbidity of patients selected for biologic treatment should ascertained. British investigators, therefore, carried out a

national, prospective, observational study to identify the prevalence and types of comorbidity in RA patients treated with biologic agents. This is a preview of subscription content, access

via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue Learn more Buy

this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: *

Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE High initial

levels of comorbidity in patients with RA selected to receive biologic agents. _Nat Rev Rheumatol_ 2, 525 (2006). https://doi.org/10.1038/ncprheum0294 Download citation * Issue Date: October

2006 * DOI: https://doi.org/10.1038/ncprheum0294 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is

not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative